Patients with COVID-19 who had the highest quartile of serum uric acid at hospital admission had increased odds of acute kidney injury.
New analysis suggests that gout prevalence is 21% among patients on peritoneal dialysis and 13% among those on hemodialysis.
New findings complement previous research showing no renoprotective effect of urate-lowering therapy in patients with chronic kidney disease.
In a study of kidney transplant recipients treated with pegloticase for uncontrolled gout, the proportion of patients experiencing gout flares declined over the treatment period.
Some 15% of patients receiving dialysis in the United States have a gout diagnosis, according to a recent study.